Litcius/Paper detail

Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy

Yan-Ruide Li, Yang Zhou, Kwang Gi Kim, Yanni Zhu, Feiyang Ma, Jiaji Yu, Yu-Chen Wang, Xianhui Chen, Zhe Li, Samuel Zeng, Xi Wang, Derek Lee, Josh Ku, Tasha Tsao, Christian Hardoy, Jie Huang, Donghui Cheng, Amélie Montel‐Hagen, Christopher S. Seet, Gay M. Crooks, Sarah Larson, Joshua Sasine, Xiaoyan Wang, Matteo Pellegrini, Antoni Ribas, Donald B. Kohn, Owen N. Witte, Pin Wang, Lili Yang

2021Cell Reports Medicine104 citationsDOIOpen Access PDF

Abstract

HSC-iNKT cell products and lay a foundation for their translational and clinical development.

Topics & Concepts

ImmunogenicityImmunotherapyImmune systemCell therapyImmunologyCancer immunotherapyChimeric antigen receptorCancer researchBiologyAntigenCancer cellCancerStem cellHaematopoiesisCell biologyGeneticsImmune Cell Function and InteractionCAR-T cell therapy researchHematopoietic Stem Cell Transplantation
Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy | Litcius